New Three-Year Real-World Data on Leqembi Revealed at CTAD 2026 Conference

New Insights on Leqembi from CTAD 2026



At the recent 19th Clinical Trials on Alzheimer's Disease (CTAD) conference held in Boston, BioArctic AB's partner Eisai unveiled pivotal findings from the real-world study named LEADER, focusing on the effects of Lecanemab, marketed as Leqembi, in early Alzheimer's disease. This presentation not only marks a significant milestone in Alzheimer's research but also provides invaluable data on the medication's effectiveness in real-world scenarios.

Study Overview


The LEADER study is a multicenter retrospective analysis involving 560 patients who received Leqembi treatment across 13 clinical sites in the United States. The data indicates a remarkable 76% reduction in the rate of progression to moderate or severe dementia among patients treated with Leqembi over the span of 36 months.

Key Findings


1. Progression Rates: Patients in the LEADER study exhibited significantly slower progression of Alzheimer's disease compared to a matched cohort from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Specifically, the hazard ratio was 0.24 (95% CI, 0.15–0.39), demonstrating the effectiveness of Leqembi in delaying the disease's advancement.
2. Stability and Improvement: Of the patients assessed after approximately 18 months, a staggering 81.1% were either stable or showed improvement from their baseline disease stage. This includes a 75.8% rate of stability and a 5.3% rate of improvement in cognitive function.
3. Treatment Adherence: Notably, 87.5% of patients remained on Leqembi at the time of data extraction, with an average treatment duration of 19 months, highlighting the medication's persistence in clinical use.

Efficacy in Different Demographics


The results remained consistent across various demographic factors, including sex, race, ethnicity, and APOE genotype. This broad applicability reinforces the potential utility of Leqembi across diverse populations.

Real-World Implications of Amyloid Clearance


Moreover, real-world evidence has emerged showcasing the efficacy of Leqembi in amyloid clearance. Among patients monitored via PET scans, 77% were found to be amyloid-negative after a median follow-up of 18.1 months, significant progress in tackling the underlying pathology of Alzheimer's disease.

Maintenance Therapy Experience


The study also discussed treatment transitions to maintenance therapy, where 91.7% of patients continued with Leqembi after reaching 18 months of treatment. A subgroup of patients successfully switched to subcutaneous maintenance treatment, which was approved recently.

Safety Profile


Safety remains a priority, and throughout the study, no significant adverse events were reported during the subcutaneous maintenance period. Isolated ARIA-H events—related to amyloid treatment—were reported in just 0.5% of patients during the intravenous maintenance phase, showing a favorable safety profile.

Gender-Based Findings


Interestingly, the stability rates were reported at 79.3% for women and 83.3% for men, reflecting similar efficacy across genders. The duration of treatment and adherence rates were almost identical as well, with 86.0% of women and 88.9% of men remaining on therapy when data was collected.

Aligning with Real-World Expectations


In addition to the LEADER results, an independent meta-analysis of 16 real-world studies involving approximately 5,000 patients supported the findings, reporting lower rates of ARIA compared to clinical trial data, further stressing the real-world applicability of Leqembi treatments.

Conclusion


The results shared at CTAD 2026 signify a vital leap in understanding Leqembi’s effectiveness for early Alzheimer's disease patients. As the global community continues to confront the Alzheimer's epidemic, these insights offer hope for enhanced treatment regimens that can change the course of the disease. BioArctic and Eisai's commitment to advancing research and treatment options is commendable, as they continue to pave the way for better outcomes in Alzheimer's care.

For further details, please refer to the official publications and discussions stemming from the CTAD conference.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.